ENZN Key Stats
| Income Statement | |
| Revenue TTM | 42.60M |
| Revenue Quarterly YoY Growth | 6.35% |
| EPS Diluted TTM | -0.077 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -2.783M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -48.45% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 136.85M |
| Enterprise Value | 55.96M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 1.766 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 1.495 |
| Free Cash Flow | 6.391M |
| Return on Equity | -1.65% |
ENZN News
- ENZN July Options Begin Trading May 20
- Special Dividend and Ongoing Cash Distribution May 14
- Billionaire Seth Klarman's Long-Term Stock Picks May 13
- Seth Klarman's Worst Performing Stock Picks Year-To-Date May 13
- ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 10
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 6
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements... Apr 23
- Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $... Apr 23
- UPDATE: Enzon Reported Concluded Review of Possible Sale of Assets, Authorizes $... Apr 23
- Enzon concludes review of possible asset sale, sale of company, announces specia... Apr 23
ENZN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Enzon Pharmaceuticals is up 46.63% over the last year vs S&P 500 Total Return up 31.95%, Merck up 30.26%, and Vertex Pharmaceuticals up 29.52%.
ENZN Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ENZN related companies
Pro Ratings for ENZN
Pro Report PDF for ENZN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download ENZN Pro Report PDF
Pro Strategies Featuring ENZN
Did Enzon Pharmaceuticals make it into our Pro Portfolio Strategies?
ENZN Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Other ENZN Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ENZN | 3.13 | +0.00 | +0.00% | 136.85M |
